欧洲 T 细胞治疗市场预测至 2030 年 - 区域分析 - 按模式（研究和商业化）、治疗类型 [CAR T 细胞疗法和基于 T 细胞受体 (TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）
No. of Pages: 78 | Report Code: BMIRE00029308 | Category: Life Sciences
No. of Pages: 78 | Report Code: BMIRE00029308 | Category: Life Sciences
T细胞疗法的优点包括靶向治疗、更快更有效的恢复以及减少副作用。在全球范围内，由于获得了各种批准，细胞疗法被广泛采用。例如，
2023 年：欧盟委员会批准了 Breyanzi（lisocabtagene maraleucel；liso-cel），这是一种针对 CD19 的嵌合抗原受体 (CAR) T 细胞疗法。 CAR T 细胞疗法中发现的 4-1BB 共刺激结构域可增强 CAR T 细胞的扩增和持久性。一线化疗难治的高级别 B 细胞淋巴瘤 (HGBCL)、弥漫性大 B 细胞淋巴瘤 (DLBCL)、原发性纵隔大 B 细胞淋巴瘤 (PMBCL) 和 3B 级滤泡性淋巴瘤 (FL3B) 的成人或完成治疗后一年内复发的患者有资格接受这种治疗。
2022 年：经欧洲人用药品委员会 (CHMP) 批准，Atara Biotherapeutics 的 Ebvallo 将成为全球首个首个获得许可的同种异体 T 细胞疗法。
2022 年：吉利德公司旗下 Kite 宣布 Yescarta (axicabtagene ciloleucel) 已获得欧盟委员会批准用于治疗患有高级别 B- 细胞的成人患者一线化疗难治的细胞淋巴瘤 (HGBL) 和弥漫性大 B 细胞淋巴瘤 (DLBCL) 或完成化疗后一年内复发的患者。
因此，T- 疗法的批准数量不断增加细胞治疗正在推动市场增长。
欧洲 T 细胞治疗市场分为德国、英国、法国、意大利、西班牙和欧洲其他国家。德国和英国等国家预计将成为该地区市场的最大贡献者。血液系统恶性肿瘤和实体瘤患病率的上升以及随后 T 细胞疗法批准的增加是推动欧洲市场增长的主要因素。
根据国家卫生服务 (NHS) 的数据，约 800 人在英国，每年有约 5,500 人被诊断出患有急性淋巴细胞白血病，而在英国，每年约有 5,500 人被诊断出患有 B 细胞淋巴瘤。由于英国白血病和淋巴瘤的流行，人们选择 T 细胞疗法来治疗这些癌症。由于 T 细胞疗法的知名度和积极成果，NHS 已与阿斯利康等多家公司达成协议，以扩大个性化 CAR T 细胞疗法的使用范围。
欧洲 T 细胞治疗市场是细分为模式、治疗类型、适应症和国家。
根据模式，欧洲 T 细胞治疗市场分为研究和商业化。到2022年，商业化细分市场将占据更大的市场份额。
根据治疗类型，欧洲T细胞治疗市场分为CAR T细胞疗法和T细胞受体（TCR）疗法。到2022年，CAR T细胞治疗领域将占据更大的市场份额。
根据适应症，欧洲T细胞治疗市场分为血液恶性肿瘤和实体瘤。到 2022 年，血液恶性肿瘤细分市场占据最大的市场份额。
按照国家/地区，欧洲 T 细胞治疗市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。德国在 2022 年主导欧洲 T 细胞治疗市场。
百时美施贵宝公司、吉利德科学公司、Immunocore Holdings Plc、信达生物制剂公司、杨森全球服务有限责任公司、传奇生物科技公司和诺华公司是其中一些欧洲 T 细胞治疗市场的领先公司。
Strategic insights for Europe T Cell Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 699.24 Million |
| Market Size by 2030 | US$ 2,345.49 Million |
| Global CAGR (2022 - 2030) | 16.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By 模式
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe T Cell Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
1. Bristol-Myers Squibb Co
2. Gilead Sciences Inc
3. Immunocore Holdings Plc
4. Innovent Biologics Inc
5. Janssen Global Services LLC
6. Legend Biotech Corp
7. Novartis AG
The Europe T Cell Therapy Market is valued at US$ 699.24 Million in 2022, it is projected to reach US$ 2,345.49 Million by 2030.
As per our report Europe T Cell Therapy Market, the market size is valued at US$ 699.24 Million in 2022, projecting it to reach US$ 2,345.49 Million by 2030. This translates to a CAGR of approximately 16.3% during the forecast period.
The Europe T Cell Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe T Cell Therapy Market report:
The Europe T Cell Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe T Cell Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe T Cell Therapy Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe T Cell Therapy Market
